Day One Reports Second Quarter 2022 Financial Results and Corporate Progress

Posted: August 5, 2022 at 2:03 am

Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in the first quarter of 2023

Read the original here:
Day One Reports Second Quarter 2022 Financial Results and Corporate Progress

Related Posts